SCHEMBL5440530

SCHEMBL5440530

Fc1cc(-c2cccc3c(Nc4ccc5ncccc5c4)nccc23)ccc1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.44
FAAH O00519 1/20 0.42
EGFR P00533 6/20 0.42
ERBB2 P04626 5/20 0.42
TGFBR1 P36897 1/20 0.41
ERBB4 Q15303 2/20 0.40
AURKA O14965 1/20 0.39
GRM4 Q14833 1/20 0.39
CHEK2 O96017 1/20 0.38
ROS1 P08922 1/20 0.38
FLT3 P36888 1/20 0.38
AURKB Q96GD4 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
GRM5 P41594 1/20 0.37
PPARG P37231 1/20 0.37
STK10 O94804 1/20 0.37
SLK Q9H2G2 1/20 0.37
C5AR1 P21730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440546 0.81 EGFR (0.45) DYRK1AEGFRERBB2TGFBR1ERBB4
SCHEMBL5447665 0.78 EGFR (0.49) EGFRERBB2TGFBR1ERBB4GRM4
SCHEMBL5437478 0.77 ABCG2 (0.48) EGFRERBB2TGFBR1ERBB4GRM4
SCHEMBL4508756 0.77 EGFR (0.59) DYRK1AFAAHEGFRERBB2TGFBR1
SCHEMBL5440513 0.77 EGFR (0.46) EGFRERBB2TGFBR1ERBB4GRM4
SCHEMBL5452047 0.74 EGFR (0.43) DYRK1AFAAHEGFRERBB2TGFBR1
SCHEMBL5446058 0.74 EGFR (0.45) FAAHEGFRERBB2TGFBR1ERBB4
SCHEMBL5440959 0.73 EGFR (0.47) EGFRERBB2TGFBR1ERBB4GRM4
SCHEMBL5446070 0.73 TGFBR1 (0.46) EGFRERBB2TGFBR1ERBB4GRM4
SCHEMBL5445026 0.72 EGFR (0.45) DYRK1AEGFRERBB2TGFBR1ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
EP-1689718-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
WO-2005049577-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 ALK, NPR3, CBR3 DYRK1A 2135/4885FAAH 2043/4885EGFR 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.